Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: A multicenter dose-escalation study

Annals of Oncology

Volumn 10, Issue 5, 1999, Pages 547-552

  Kouroussis, C ^b   Xydakis, E ^b   Potamianou, A ^b   Giannakakis, T ^b   Kakolyris, S ^b   Agelaki, S ^b   Sara, E ^b   Malamos, N ^b   Alexopoulos, A ^b   Mavroudis, D ^b   Samonis, G ^b   Papadouris, S ^b   Georgoulias, V ^a   Panagos, G ^b  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b NONE

Author keywords

Breast cancer; Docetaxel; Epirubicin

Indexed keywords

DOCETAXEL; EPIRUBICIN;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST METASTASIS; CLINICAL ARTICLE; DISEASE COURSE; DOSE RESPONSE; DRUG TOLERABILITY; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEUTROPENIA; PRIORITY JOURNAL; RESPONSE TIME; TREATMENT OUTCOME; TUMOR GROWTH;

EID: 0033053285     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026441804889     Document Type: Article

References (21)

1. Henderson IC. Chemotherapy for metastatic disease. In Harris JR, Hellman S, Henderson IC, Kinne DW (eds): Breast Diseases, Fourth Edition. Philadelphia: Lippincott 1991; 604-65.
2. Mouridsen HT. Systemic therapy of advanced breast cancer. Drugs 1992; 44 (Suppl 4): 17-28.
3. Zoli W, Flamigni A, Frassineti GL et al. In vitro activity of Taxol and taxotere in comparison with doxorubicin and cisplatin on primary cell cultures of human breast cancers. Breast Cancer Res 1995; 34: 63-9.
4. Fumoleau P. Treatment of patients with liver metastases. Anti-cancer Drugs 1996; 7 (Suppl 2): 21-33.
5. Italian Multicenter Breast Study with epirubicin. Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide vs. fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: An Italian multicenter trial. J Clin Oncol 1988; 6: 976-82.
6. Ravdin P, Valero V, Burris H et al. Phase II trial of docetaxel in advanced anthracycline resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995; 13: 2879-85.
7. Gehl J, Boesgaard M, Paaske T et al. Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic. Ann Oncol 1996; 7: 687-93.
8. Verweij J, Clavel M, Chevallier B. Paclitaxel (Taxol) and docetaxel (Taxotere): Not simply two of a kind. Ann Oncol 1994; 5: 495-505.
9. Dieras V. Docetaxel in combination with doxorubicin: A phase I dose-finding study. Oncology 1997; 11 (Suppl 6): 1820.
10. Misset JL, Dieras V, Bozec L et al. Long-term follow-up of the phase I-II study of docetaxel (D) and doxorubicin (Dx) as first-line CT of metastatic breast cancer (MBC). Proc Am Assoc Clin Oncol 1998, 17: 174a (Abstr 613).
11. Itoh K, Fugii H, Minami H et al. Phase I and pharmacologic study of docetaxel combined with doxorubicin for advanced breast cancer. Proc Am Soc Clin Oncol 1997; 16:174a (Abstr 610).
12. Kerbrat P, Viens P, Roche H et al. Docetaxel (D) in combination with epirubicin (E) as first-line chemotherapy (CT) of metastatic breast cancer (MBC): Final results. Proc Am Soc Clin Oncol 1998; 17:151a (Abstr 579).
13. Raab G, Borquez D, Harstrick A et al. Phase I study of docetaxel (D) in combination with epirubicin (E) as first-line chemotherapy (CT) in metastatic breast cancer. Proc Am Soc Oncol 1998; 18: 168a (Abstr 644).
14. Pagani O, Aapro M, Martinelli G et al. Dose-finding study of high-dose epirubicin (E) and docetaxel (T) as first-line chemotherapy in advanced breast cancer (ABC). ECCO Hamburg Eur J Cancer 1997; 33 (Suppl 8): S147 (Abstr 654).
15. Trudeau ME, Crump M, Latreille J et al. Escalating doses of docetaxel and epirubicin as first-line therapy for metastatic breast cancer: A phase I study of the National Cancer Institute of Canada-Clinical Trials Group. Proc Am Soc Clin Oncol 1998; 17: 178a (Abstr 687).
16. Launchbury AP, Habboubi N. Epirubicin and doxorubicin: A comparison of their characteristics, therapeutic activity and toxicity. Cancer Treat Rev 1993; 19: 197-228.
17. Ganzina F. 4′-Epi-doxorubicin, a new analogue of doxorubicin: A preliminary overview of preclinical and clinical data. Cancer Treat Rev 1983; 10: 1-22.
18. Hurteloup P, Cappelaere P, Armand JP et al. Phase II clinical evaluation of 4′-Epidoxorubicin. Cancer Treat Rep 1983, 67: 337-41.
19. Gianni L, Bigano L, Locatelli A et al. Human pharmocokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol 1997; 15: 1906-15.
20. Miller AB, Hoogstraten B, Staguet M et al. Reporting results of cancer research. Cancer 1981; 47: 207-41.
21. Dieras V. Taxanes in combination with doxorubicin in the treatment of metastatic breast cancer. Semin Oncol 1998; 25 (5, Suppl 12): 18-22.